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Malignant tumors escape from host immune surveillance
through multiple mechanisms. Of these, abnormal tumor
vasculature and hypoxia are critical in establishing
an immunosuppressive tumor microenvironment, and
consequently, impeding an active cancer immunotherapy.
Thus, we hypothesized that vascular normalization can
recondition the tumor immune microenvironment and
enhance a cancer immunotherapy. Here, we compared the
dosage effects of anti-vascular endothelial growth factor
receptor 2 antibody (DC101) treatments on tumor vascu-
lature, and demonstrated that appropriate low dose
DC101 treatment significantly improves functional tumor
vessels and reduces tissue hypoxia, compared to control or
high dose DC101 treatment in orthotopic preclinical
breast tumor models. Consistently, our flow cytometry
and gene profile analysis data showed that the lower doses
are superior to the high doses at polarizing perivascular
tumor-associated macrophages (TAMs) from M2-like
to M1-like phenotype, in facilitating CD8+ T cell tumor
infiltration, while reducing myeloid-derived suppressor
cells (MDSCs) in the tumor parenchyma. Based on this
mechanism, synchronizing vascular normalization with
T cell activation induced by a whole cancer cell vaccine
therapy significantly enhanced anti-cancer efficacy in a
CD8+ T cell-dependent manner in both orthotopic and
spontaneous breast cancer models. These findings indicate
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Figure 1 Lower “Vascular normalizing” dose of anti-angiogenic treatment reprograms the tumor microenvironment from immunosuppressive to
immunosupportive.
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that vascular normalizing lower doses of anti-VEGFR2
antibody treatment can reprogram the tumor microenvir-
onment away from immunosuppression toward potentia-
tion of cancer vaccine therapies (Figure 1). Given that
anti-angiogenic treatment is an established therapy in
several solid cancers, our study suggests a potential trans-
lational strategy to improve the efficacy of cancer immu-
notherapies in clinic by combining with judicious low dose
of anti-angiogenic treatments.
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